These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34809430)

  • 41. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure of the homodimeric androgen receptor ligand-binding domain.
    Nadal M; Prekovic S; Gallastegui N; Helsen C; Abella M; Zielinska K; Gay M; Vilaseca M; Taulès M; Houtsmuller AB; van Royen ME; Claessens F; Fuentes-Prior P; Estébanez-Perpiñá E
    Nat Commun; 2017 Feb; 8():14388. PubMed ID: 28165461
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The discovery of novel human androgen receptor antagonist chemotypes using a combined pharmacophore screening procedure.
    Voet A; Helsen C; Zhang KY; Claessens F
    ChemMedChem; 2013 Apr; 8(4):644-51. PubMed ID: 23436650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
    Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
    Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
    Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
    Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
    Guo C; Pairish M; Linton A; Kephart S; Ornelas M; Nagata A; Burke B; Dong L; Engebretsen J; Fanjul AN
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2572-8. PubMed ID: 22377517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.
    Tang Q; Fu W; Zhang M; Wang E; Shan L; Chai X; Pang J; Wang X; Xu X; Xu L; Li D; Sheng R; Hou T
    Eur J Med Chem; 2020 Apr; 192():112156. PubMed ID: 32114360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
    Siddique HR; Mishra SK; Karnes RJ; Saleem M
    Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists.
    Roell D; Rösler TW; Hessenkemper W; Kraft F; Hauschild M; Bartsch S; Abraham TE; Houtsmuller AB; Matusch R; van Royen ME; Baniahmad A
    J Steroid Biochem Mol Biol; 2019 Apr; 188():59-70. PubMed ID: 30615932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery.
    Sakkiah S; Ng HW; Tong W; Hong H
    Expert Opin Ther Targets; 2016 Oct; 20(10):1267-82. PubMed ID: 27195510
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of persistent organic pollutants binding modes with androgen receptor ligand binding domain by docking and molecular dynamics.
    Xu XJ; Su JG; Bizzarri AR; Cannistraro S; Liu M; Zeng Y; Chen WZ; Wang CX
    BMC Struct Biol; 2013 Sep; 13():16. PubMed ID: 24053684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allosteric conversation in the androgen receptor ligand-binding domain surfaces.
    Grosdidier S; Carbó LR; Buzón V; Brooke G; Nguyen P; Baxter JD; Bevan C; Webb P; Estébanez-Perpiñá E; Fernández-Recio J
    Mol Endocrinol; 2012 Jul; 26(7):1078-90. PubMed ID: 22653923
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging.
    Gustafson JL; Neklesa TK; Cox CS; Roth AG; Buckley DL; Tae HS; Sundberg TB; Stagg DB; Hines J; McDonnell DP; Norris JD; Crews CM
    Angew Chem Int Ed Engl; 2015 Aug; 54(33):9659-62. PubMed ID: 26083457
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
    Chen C; Chai X; Hu X; Lou S; Li D; Hou T; Cui S
    J Med Chem; 2022 Oct; 65(19):13074-13093. PubMed ID: 36154033
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Specific interactions between androgen receptor and its ligand: ab initio molecular orbital calculations in water.
    Kobayashi I; Takeda R; Suzuki R; Shimamura K; Ishimura H; Kadoya R; Kawai K; Takimoto-Kamimura M; Kurita N
    J Mol Graph Model; 2017 Aug; 75():383-389. PubMed ID: 28641211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
    Liu H; Han R; Li J; Liu H; Zheng L
    J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
    Wu M; Xie Y; Cui X; Huang C; Zhang R; He Y; Li X; Liu M; Cen S; Zhou J
    Eur J Med Chem; 2019 Mar; 166():232-242. PubMed ID: 30711833
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and synthesis of novel androgen receptor antagonists via molecular modeling.
    Zhao C; Choi YH; Khadka DB; Jin Y; Lee KY; Cho WJ
    Bioorg Med Chem; 2016 Feb; 24(4):789-801. PubMed ID: 26780832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
    Xu X; Du Q; Meng Y; Li Z; Wu H; Li Y; Zhao Z; Ge R; Lu X; Xue S; Chen X; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2020 Apr; 192():112196. PubMed ID: 32169785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of drugs that directly target the intrinsically disordered region of the androgen receptor.
    Sadar MD
    Expert Opin Drug Discov; 2020 May; 15(5):551-560. PubMed ID: 32100577
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.